Patients First, Improve The Lives.

Cultivating the humanity and liberty,
Realize the open innovation,
Generate proof-of concept clinical data.

PIPELINE

ABOUT US

Aston Sci. is a clinical stage company, based South Korea.
Aston Sci. strives to innovate the paradigm of drug development based on the open innovation, in oncology, CNS disease, and geriatric medicine.
Aston Sci. has been focusing on generating compelling proof of concept clinical data of investigational drugs.

Our company strives to innovate the medicine to improve patient’s lives.

PEOPLE

MANAGEMENT

  • Hun Jung, MD. PhD.

    Chief Executive Officer

    Hun Jung, M.D./Ph.D., has served as Chief Executive Officer of Aston Sci., along with sitting on the founder and the Board of Directors, since Oct. 2018. Dr. Jung brings to Aston Sci. more than 19 years of clinical experience, including nearly 9 years in the pharmaceutical industry leading translational research, clinical development, and medical affairs of oncology drug. Dr. Jung founded Aston Sci. with enriched experiences of MSD (Merck & Co.) and Samsung Bioepis. As a clinician of general surgery at Catholic Medical Center and Samsung Medical Center, Dr. Jung conducted preclinical and clinical researches in GI oncology. Prior to that, he was a general surgery resident at College of Medicine, the Catholic University of Korea. Also, he has been continuously contributing his efforts in activities of oncology medical societies.

  • Harry Hunwoo Shin, PhD.

    VP, Chief Business Officer

    Harry Hunwoo Shin,. Before joining Aston Science, Harry served MSD (Merck in USA) for 3 years as business development director to scout and develop business development opportunities for pharmaceutical pipelines sprouting from Korea. Previously, Harry worked at Korea Health Industry Development Institute (KHIDI) for 2.5 years as a exec. consultant to facilitate global licensing deal for Korean companies’ pipelines. Before joining KHIDI, Harry worked at SK Bio-Pharm (NJ/Korea) for 18 years as a medicinal chemist, research program director and business development director.

  • In Hiring Process

    Chief Medical Officer

WORKING TOGETHER WITH

  • Eunkyo Joung, MD.

    Clinical Director

  • Jiyun Lee, MPH.

    Clinical Project Director

  • Minji Yu

    Clinical Project Manager

  • Eunsun Kwon

    Business Development Director

  • Jung Yim

    Executive Administrator

  • Ashley Youngmin Kim

    External Project Manager

BOARD OF DIRECTOR

  • Hun Jung, MD

  • Harry Shin, PhD

  • HaeMyoung Jeon, MD

  • MinSeop Song

FOUNDERS

  • Hun Jung, MD

  • Harry Shin, PhD

  • Jihyun Kim, MD

  • Cwangkwang Chung

  • Ilboo Kim

  • Yeojin Jung

BUSINESS MODEL

CAPABILITY

PIPELINE

NEWS

제3자배정 유상증자 신주발행 공고

작성자
jungyim
작성일
2019-11-13 12:27
조회
35040
 제3자배정 유상증자 신주발행 공고 [첨부]

 

당사는 2019. 11. 13. 자 이사회에서 상법 제418조 제2항 및 당사 정관 제11조 제2항의 규정에 의하여 첨부와 같이 신주를 발행하기로 결의하였으므로 상법 제418조 제4항에 따라 이를 공고 합니다.

 

 

 

주식회사 애스톤사이언스

서울특별시 강남구 남부순환로2621,

11222호 (도곡동, 서브원 강남빌딩)

대표이사 정헌

PARTNERS

We build our Vants through partnerships with companies and academic institutions that share our commitment to developing new medicines for patients and delivering innovation in healthcare. Select partners are listed below.

CONTACT

ADDRESS : 2621, Nambusunhwan-ro, Gangnam-gu, Seoul, Republic of Korea
TEL : 02-2038-2347

법인설립 : 2018. 10. (since 2018)
법인등록번호 : 110111-6876423
사업자등록번호 : 354-88-01258
벤처기업인증번호 : 20190300687 (2019. 07.)

(주)애스톤사이언스는 개인정보보호법을 준수합니다.

NAME

E-MAIL ADDRESS

COMMENTS